Medicina clinica
The most recent articles from:
February 2024
-
Case Reports
Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.
Emicizumab is the first non-replacement therapy for prophylaxis in severe hemophilia A. ⋯ This study demonstrated emicizumab pharmacokinetics and its half life ensure optimal levels with prophylaxis treatment at doses established in the technical data sheet.